Prediction of health preference values from CD4 counts in individuals with HIV

Medical Decision Making

Volumn 33, Issue 4, 2013, Pages 558-566

  Isogai, Pierre K ^a   Rueda, Sergio ^b,c   Rachlis, Anita R ^a,c   Rourke, Sean B ^b,c   Mittmann, Nicole ^a,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b ONTARIO HIV TREATMENT NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

CD4 count; health preference; health utility score; HIV; model

Indexed keywords

ADULT; CANADA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; HEALTH STATUS; HIV INFECTIONS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; STATISTICAL MODEL; ARTICLE; HEALTH PREFERENCE; HEALTH UTILITY SCORE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MODEL;

ADULT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HEALTH STATUS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; ONTARIO; QUALITY OF LIFE; QUESTIONNAIRES;

CD4 COUNT; HEALTH PREFERENCE; HEALTH UTILITY SCORE; HIV; MODEL;

EID: 84877049067     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X12453499     Document Type: Article

References (36)

1. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada [3rd edition]. 2006. Ottawa. Available from: URL: http://cadth.ca/media/pdf/186-EconomicGuidelines-e.pdf
2. National Institute for Health and Clinical Excellence. Guides to the methods of technology appraisal. 2010. Available from: URL: http://www.nice.org. uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
3. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics. 1995 ; 7 (6). 490-502
4. Nosyk B, Sun H, Bansback N, et al. The concurrent validity and responsiveness of the Health Utilities Index (HUI 3) among patients with advanced HIV/AIDS. Qual Life Res. 2009 ; 18 (7). 815-24
5. Anis AH, Nosyk B, Sun H, et al. Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr. 2009 ; 51 (5). 631-9
6. Braithwaite RS, Goulet J, Kudel I, Tsevat J, Justice AC. Quantifying the decrement in utility from perceived side effects of combination antiretroviral therapies in patients with HIV. Value Health. 2008 ; 11 (5). 975-9
7. Joyce VR, Barnett PG, Bayoumi AM, et al. Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease. J Acquir Immune Defic Syndr. 2009 ; 50 (1). 27-36
8. Kauf TL, Roskell N, Shearer A, et al. A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health. 2008 ; 11 (7). 1144-53
9. Sakthong P, Schommer JC, Gross CR, Prasithsirikul W, Sakulbumrungsil R. Health utilities in patients with HIV/AIDS in Thailand. Value Health. 2009 ; 12 (2). 377-84
10. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making. 2002 ; 22 (1). 27-38
11. Stavem K, Froland SS, Hellum KB. Comparison of preferencebased utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS. Qual Life Res. 2005 ; 14 (4). 971-80
12. Bayoumi AM, Redelmeier DA. Economic methods for measuring the quality of life associated with HIV infection. Qual Life Res. 1999 ; 8 (6). 471-80
13. Tsevat J, Solzan JG, Kuntz KM, et al. Health values of patients infected with human immunodeficiency virus: relationship to mental health and physical functioning. Med Care. 1996 ; 34 (1). 44-57
14. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002 ; 22 (6). 475-81
15. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008 ; 372 (9635). 293-9
16. King JT, Justice AC, Roberts MS, Chang CC, Fusco JS. Longterm HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med Decis Making. 2003 ; 23 (1). 9-20
17. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010 ; 50 (10). 1387-96
18. Ray M, Logan R, Sterne JA, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2010 ; 24 (1). 123-37
19. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009 ; 27 (6). 884-90
20. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007 ; 356 (17). 1723-35
21. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008 ; 359 (14). 1429-41
22. Crum-Cianflone NF, Grandits G, Echols S, et al. Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use?. J Acquir Immune Defic Syndr. 2010 ; 54 (3). 248-57
23. Grabar S, Le M, V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000 ; 133 (6). 401-10
24. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009 ; 360 (18). 1815-26
25. World Health Organization (WHO). Priority interventions: HIV/AIDS prevention, treatment and care in the health sector. Geneva, Switzerland: WHO; 2010. Available from: URL: http://whqlibdoc.who.int/publications/2010/ 9789241500234-eng.pdf
26. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services; 2011. Available from: URL: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
27. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010 ; 304 (3). 321-33
28. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003 ; 1: 54
29. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999 ; 15 (2). 141-55
30. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009 ; 338: a3172
31. Martin J, Volberding P. HIV and premature aging: a field still in its infancy. Ann Intern Med. 2010 ; 153 (7). 477-9
32. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007 ; 44 (3). 441-6
33. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005 ; 41 (3). 361-72
34. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003 ; 163 (18). 2187-95
35. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005 ; 43 (3). 203-20
36. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004 ; 42 (9). 851-9